BC PharmaCare: Your Voice

Get Involved


Read the Ongoing Results of this Engagement

What is this engagement about?

The Ministry of Health has two main goals for the BC PharmaCare program:

  • To cover drugs that support the health and well-being of British Columbians; and
  • To make sure that the drugs PharmaCare covers are affordable and give the best value for money.

To meet the first goal, PharmaCare covers a drug only if it has a proven record of safety and effectiveness. To meet the second goal, PharmaCare compares each drug to the drugs it already covers that treat the same condition. For example, if more than one drug provides the same health benefit, PharmaCare may cover only the drug(s) that offers the best value.

Before PharmaCare decides if it will cover a drug, the drug goes through a full review to find out if covering it aligns
with the goals above. Patients, caregivers and patient groups have the opportunity to add their voices to the drug
review process.

Drug(s) available for input:

    • Generic name: patiromer
      Brand name: Veltassa®
      Drug used for: the treatment of hyperkalemia in adults with chronic kidney disease
    • Generic name: semaglutide
      Brand name: Rybelsus®
      Drug used for: the treatment of type 2 diabetes
    • Generic name: risdiplam
      Brand name: Evrysdi™
      Drug used for: the treatment of spinal muscular atrophy (SMA)
    • Generic name: budesonide (orodispersible tablets)
      Brand name: Jorveza™
      Drug used for: the maintenance of clinico-pathological remission in adults with eosinophilic esophagitis (EoE)
    • Generic name: luspatercept
      Brand name: Reblozyl®
      Drug used for: the treatment of adult patients with red blood cell (RBC) transfusion-dependent anemia associated with beta(β)-thalassemia

Input accepted: From Wednesday, March 24, 2021 to Wednesday, April 21, 2021 AT MIDNIGHT

To provide input, please visit http://www.gov.bc.ca/BCyourvoice.

How can my contribution make a difference?

All responses that are submitted during the open consultation are sent to the Drug Benefit Council. The Council takes the public’s input into consideration when they make their drug coverage recommendations. Drugs are posted for review on an ongoing basis.

Details of the Engagement:

Date: June 6, 2017

Status: Ongoing

Location: Province-wide

Category: Health & Safety

Types: Online

Get Involved


Read the Ongoing Results of this Engagement